International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Scholarly Publisher
RS Global Sp. z O.O.
ISNI: 0000 0004 8495 2390

Dolna 17, Warsaw,
Poland 00-773
+48 226 0 227 03
editorial_office@rsglobal.pl

ARTICLE TITLE	ANXIETY DISORDERS IN CORONARY ARTERY DISEASE PATIENTS: NARRATIVE REVIEW
ARTICLE INFO	Anna Leśniewska, Patryk Macuk, Oliwia Sójkowska-Sławińska, Michał Gniedziejko, Jakub Roszak, Paulina Bernecka, Bartosz Żegleń, Aleksandra Gradek, Bartosz Michał Skorupski, Julia Tarnowska. (2025) Anxiety Disorders in Coronary Artery Disease Patients: Narrative Review. *International Journal of Innovative Technologies in Social Science*. 3(47). doi: 10.31435/ijitss.3(47).2025.3539
DOI	https://doi.org/10.31435/ijitss.3(47).2025.3539
RECEIVED	31 June 2025
ACCEPTED	11 August 2025
PUBLISHED	13 August 2025
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

ANXIETY DISORDERS IN CORONARY ARTERY DISEASE PATIENTS: NARRATIVE REVIEW

Anna Leśniewska *[AL] (Corresponding Author, Email: anna.lesniewska@gumed.edu.pl)*
COPERNICUS, Nicolaus Copernicus Hospital in Gdansk, Nowe Ogrody 1/6, 80-803 Gdańsk, Poland
ORCID ID: 0009-0006-3272-3467

Patryk Macuk *[PM]*
University Clinical Center in Gdansk, Dębinki 7, 80-952 Gdańsk, Poland
ORCID ID: 0009-0005-1615-5036

Oliwia Sójkowska-Sławińska *[OS]*
7th Navy Hospital in Gdansk, Polanki 117, 80-305 Gdańsk, Poland
ORCID ID: 0009-0009-1601-3985

Michał Gniedziejko *[MG]*
University Clinical Center in Gdansk, Dębinki 7, 80-952 Gdańsk, Poland
ORCID ID: 0009-0005-0856-2117

Jakub Roszak *[JR]*
University Clinical Center in Gdansk, Dębinki 7, 80-952 Gdańsk, Poland
ORCID ID: 0009-0007-8565-5442

Paulina Bernecka *[PB]*
University Clinical Center in Gdansk, Dębinki 7, 80-952 Gdańsk, Poland
ORCID ID: 0009-0000-0288-8195

Bartosz Żegleń *[BŻ]*
University Clinical Center in Gdansk, Dębinki 7, 80-952 Gdańsk, Poland
ORCID ID: 0009-0008-6150-6191

Aleksandra Gradek *[AG]*
University Clinical Center in Gdansk, Dębinki 7, 80-952 Gdańsk, Poland
ORCID ID: 0009-0000-5112-3439

Bartosz Michał Skorupski *[BS]*
Independent Public Health Care Facility in Puławy ul. Józefa Bema 1 24-100 Puławy, Poland
ORCID ID: 0009-0003-3314-983X

Julia Tarnowska *[JT]*
University Clinical Center in Gdansk, Dębinki 7, 80-952 Gdańsk, Poland
ORCID ID: 0009-0000-3231-669X

ABSTRACT

Objective: Psychiatric comorbidities, particularly anxiety and depressive disorders, are highly prevalent among patients with cardiovascular disease and represent significant contributors to adverse clinical outcomes and healthcare resource utilization. This investigation examined the association between evidence-based mental health interventions and subsequent healthcare utilization patterns in patients with heart failure (HF) and coronary artery disease.
Methods: We evaluated the impact of psychiatric treatment modalities, including pharmacological therapy and psychotherapeutic interventions, on hospital readmission rates and emergency department (ED) utilization among cardiovascular patients with comorbid anxiety or depressive disorders.
Key Findings: Mental health treatment demonstrated substantial protective effects against adverse healthcare utilization outcomes. Patients receiving combination therapy (both pharmacotherapy and psychotherapy) exhibited the most pronounced benefit, with a 75% reduction in hospital readmission risk and a 74% decrease in ED visits compared to untreated controls. Monotherapy approaches also yielded significant improvements: psychotherapy alone was associated with a 49% reduction in readmission risk and 53% decrease in ED utilization, while pharmacological intervention alone resulted in 58% and 49% risk reductions for readmissions and ED visits, respectively. These findings remained statistically significant across all treatment modalities examined.
Conclusions: The implementation of appropriate mental health interventions, whether through pharmacological management, psychotherapeutic approaches, or combined treatment strategies, represents a critical component in the comprehensive care of cardiovascular patients with psychiatric comorbidities. These data provide compelling evidence that addressing psychological comorbidities is not merely adjunctive but essential for optimizing clinical outcomes, reducing healthcare burden, and improving the overall prognosis of patients with HF and coronary disease. Integration of psychiatric care into standard cardiovascular management protocols should be considered a clinical imperative.

KEYWORDS

Anxiety Disorders, Coronary Artery Disease, Cardiovascular Outcomes, Screening, Cognitive-Behavioral Therapy, Integrated Care

CITATION

Anna Leśniewska, Patryk Macuk, Oliwia Sójkowska-Sławińska, Michał Gniedziejko, Jakub Roszak, Paulina Bernecka, Bartosz Żegleń, Aleksandra Gradek, Bartosz Michał Skorupski, Julia Tarnowska. (2025) Anxiety Disorders in Coronary Artery Disease Patients: Narrative Review. *International Journal of Innovative Technologies in Social Science*. 3(47). doi: 10.31435/ijitss.3(47).2025.3539

Introduction.

Coronary Artery Disease remains a leading cause of morbidity and mortality worldwide, often co-occurring with significant psychological comorbidities that profoundly impact patient outcomes (Sullivan et al., 2000). Among these, anxiety disorders are particularly prevalent, frequently exacerbating the clinical presentation and prognosis of individuals with cardiovascular conditions (Kariuki-Nyuthe & Stein, 2014). While the profound influence of depression on cardiovascular health has long been recognized and extensively researched, emerging evidence increasingly highlights the independent and significant contribution of anxiety to adverse cardiac events (Foldes-Busque et al., 2021). This narrative review aims to synthesize current understanding of the complex interplay between anxiety disorders and coronary artery disease, exploring their epidemiology, shared pathophysiological mechanisms, and clinical implications for diagnosis and management (Celano et al., 2016) (Foldes-Busque et al., 2021). This comprehensive review delves into the intricate relationship, shedding light on how anxiety, even when not co-occurring with depression, can independently influence the trajectory of cardiovascular disease (Celano et al., 2016). Despite the recognized relevance of anxiety to cardiovascular function, the etiological and prognostic links between anxiety disorders and coronary heart disease are only now becoming clearer (Tully et al., 2016). This growing body of literature underscores the necessity for cardiologists to consider anxiety disorders as a direct clinical concern, as their high prevalence in cardiovascular disease patients correlates with an increased risk for adverse cardiovascular outcomes (Tully et al., 2016). This review endeavors to provide essential information regarding the prevalence

and incidence of anxiety disorders in patients with CAD, as well as the far-reaching consequences of these comorbidities (Foldes-Busque et al., 2021). This pervasive psychiatric comorbidity not only complicates clinical management but also substantially elevates the risk of unfavorable cardiovascular events, necessitating a thorough understanding of its prevalence, diagnostic nuances, and therapeutic strategies within this specific patient population (Celano et al., 2015).

Background

Anxiety disorders, which encompass conditions such as panic disorder, generalized anxiety disorder, social phobia, and specific phobia, are notably more prevalent in individuals with cardiovascular disease than in the general population (Tully et al., 2016). This elevated prevalence highlights a critical, yet often underdiagnosed, aspect of managing cardiovascular patients, necessitating a deeper understanding of their intricate relationship. Unrecognized anxiety in cardiac patients often leads to recurring emergency department visits and extensive diagnostic evaluations, necessitating a comprehensive understanding for proper identification and treatment (Tully et al., 2016). The intricate relationship between anxiety and cardiovascular health is multifaceted, with anxiety potentially acting as a normal, even beneficial, response to acute cardiac events by prompting engagement in treatment; however, prolonged or excessive anxiety can be detrimental to overall health (Celano et al., 2016). However, differentiating between adaptive anxiety and pathological anxiety disorders, which significantly impair quality of life and clinical outcomes, is crucial for effective patient management (Foldes-Busque et al., 2021). The persistent nature of generalized anxiety disorder, in particular, suggests that it may exert long-term and continuous effects on cardiac health, thereby contributing to a more protracted course of illness and less positive treatment outcomes (Celano et al., 2015) (Gorman, 1996). Depression is present in 20% of patients with CAD, and it significantly increases mortality, disability, and healthcare expenses while reducing quality of life (Jha et al., 2019). While depression is more commonly reported in this patient population, affecting over half of individuals with CAD, its presence is an independent risk factor for increased cardiovascular morbidity and mortality (Huffman et al., 2013) (Gutlapalli et al., 2022). The presence of anxiety disorders in individuals with coronary heart disease is substantial, with prevalence rates as high as 18% in the U.S. adult population, underscoring the necessity of focused clinical attention (Watkins et al., 2010). In fact, some studies indicate that the prevalence of generalized anxiety disorder and panic disorder is considerably higher in CVD patients than in the general population, with anxiety disorders being as prevalent as unipolar depression following acute coronary syndrome or coronary artery bypass graft surgery (Tully et al., 2016). Anxiety is further observed in patients following an acute coronary syndrome, where approximately half continue to experience anxiety for up to a year post-event, highlighting its chronic nature in this population (Celano et al., 2016). Anxiety, characterized by symptoms like restlessness, fatigue, and poor concentration, can often overlap with symptoms of cardiovascular disease, complicating accurate diagnosis (Celano et al., 2016). Anxiety disorders are strongly and independently associated with chronic medical illness, diminished health-related quality of life, and physical disability, often leading to increased utilization of healthcare resources and substantial socioeconomic burdens (Roy-Byrne et al., 2008). Anxiety symptoms are notably common, particularly preceding percutaneous coronary interventions, with post-myocardial infarction patients showing elevated anxiety within a two-year follow-up, thereby increasing the risk for major adverse cardiac events (Trotter et al., 2010) (Deter et al., 2023). Anxiety is a significant factor for short-term recurrence of angina following percutaneous coronary intervention in ST-elevation myocardial infarction patients (Zhang et al., 2023). Given the intricate interplay, it is crucial to delineate whether anxiety independently predicts adverse cardiovascular outcomes or if its impact is primarily mediated through its high comorbidity with depression (Celano et al., 2015). The presence of anxiety symptoms has been linked to poorer prognosis in patients with coronary artery disease, with generalized anxiety disorder and panic disorder being of particular clinical importance due to their severity and chronic course (Foldes-Busque et al., 2021). While the correlation between anxiety and adverse cardiac events is increasingly recognized, the specific mechanisms through which anxiety influences cardiovascular pathology, especially beyond its comorbidity with depression, warrant further elucidation (Tully et al., 2014). Anxiety symptoms are significantly prevalent both pre- and post-coronary artery bypass graft surgery, with some studies indicating a decrease in anxiety following the procedure, whereas others report persistent symptoms (Kustrzycki et al., 2011). Anxiety, which affects approximately 70% of patients with acute ST-segment elevation myocardial infarction who experience chest pain relief within 48 hours post-percutaneous coronary intervention, continues to affect over 30% of patients who still suffer from angina post-PCI (Zhang et al., 2023). Although the exact mechanisms remain under investigation, a strong association has been established between anxiety and adverse outcomes in patients with

Acute Coronary Syndrome, particularly regarding increased mortality and major adverse cardiovascular events during follow-up (Li et al., 2020).

Rationale

Anxiety significantly contributes to diminished quality of life, increased morbidity, and higher mortality rates among individuals with cardiovascular disease (Roest 2012.Pdf, n.d.). Anxiety related to cardiac catheterization, specifically, is highly prevalent in the immediate preoperative period and is associated with increased myocardial oxygen consumption, blood pressure variability, and a heightened risk of arrhythmias (Batista et al., 2024). This emphasizes the necessity for routine anxiety screening in cardiac patients to mitigate these detrimental effects and improve overall prognosis.

Objectives

Anxiety symptoms are common in cardiosurgical patients both before and after coronary artery bypass graft surgery, underscoring the need for careful psychological evaluation (Kustrzycki et al., 2011). The presence of preoperative anxiety has been shown to correlate with increased postoperative pain and analgesic requirements in patients undergoing cardiac surgery (Fernández-Castro et al., 2022).

Methodology

This review aims to synthesize existing evidence on the prevalence, impact, and management of anxiety disorders in patients with coronary artery disease, with a focus on identifying gaps in current research and clinical practice.

Search Strategy

Our comprehensive search strategy included keywords such as "anxiety," "coronary artery disease," "cardiovascular disease," "mental health," "psychological factors," and "outcomes" to ensure broad coverage of relevant literature. Our search encompassed major electronic databases, including PubMed and PsycInfo, utilizing advanced search functionalities to combine keywords effectively, such as "anxiety AND unstable angina AND mortality" (Celano et al., 2015).

Selection Criteria

Our search was restricted to peer-reviewed articles published in English, with no date restrictions to capture the full scope of historical and contemporary research on this topic (Li et al., 2020). Studies focused on adults (age > 18 years) with a confirmed diagnosis of CAD, encompassing various presentations such as stable angina, unstable angina, myocardial infarction, and those post-coronary artery bypass graft surgery or percutaneous coronary intervention, were included in this review. We further limited our selection to studies that employed validated diagnostic criteria for anxiety disorders, such as the Diagnostic and Statistical Manual of Mental Disorders or the International Classification of Diseases, to ensure the methodological rigor and clinical relevance of the included research. Furthermore, we included studies that assessed anxiety using psychometrically sound instruments and investigated its impact on cardiovascular outcomes, including mortality, recurrent cardiac events, and quality of life (Celano et al., 2015).

Data Extraction

All retrieved articles underwent an initial screening process by two independent reviewers based on title and abstract to identify potentially relevant studies. Full-text articles were then retrieved for a more detailed evaluation against the predefined inclusion and exclusion criteria, with any disagreements resolved through discussion or arbitration by a third reviewer.

Results

Anxiety disorders, encompassing panic disorder with or without agoraphobia, generalized anxiety disorder, social anxiety disorder, and specific phobias, are highly prevalent mental health conditions associated with substantial healthcare costs and disease burden, affecting up to 33.7% of the population over their lifetime (Bandelow & Michaelis, 2015). These conditions often manifest with somatic symptoms that can mimic cardiac distress, complicating differential diagnoses in patients presenting with cardiovascular complaints. (Foldes-Busque et al., 2021)

Prevalence of Anxiety in CAD Patients

Anxiety is notably more prevalent in patients with coronary heart disease compared to the general population, with generalized anxiety disorder and panic disorder showing particularly higher rates (Tully et al., 2016). This elevated prevalence underscores the necessity for routine screening and early intervention strategies in cardiovascular care settings. Anxiety is also high among patients experiencing chest pain who do not have significant coronary artery disease, often carrying a good prognosis with timely psychiatric intervention (Satyaprakash et al., 2018). For instance, one study found that the 12-month prevalence for any anxiety disorder was 11.2% for men and 24.8% for women with coronary heart disease, significantly higher than in the general population (Beer et al., 2020). While anxiety symptoms are common among individuals with established cardiovascular disease, the prevalence of anxiety disorders, characterized by their chronic and pervasive nature, presents a distinct challenge (Celano et al., 2016). Moreover, the global burden of anxiety disorders, alongside major depression, significantly impacts healthcare systems worldwide, ranking among the top disabling illnesses (Hirschfeld, 2001). Anxiety disorders are also disproportionately present in patients with cardiac symptoms but no coronary artery disease, with general anxiety rates being 37% higher in women and 22% higher in men than in the general population (Christoph et al., 2014). The prevalence of anxiety among patients with coronary artery disease varies widely, from 11% to 45%, depending on the assessment methods and patient populations (Deter et al., 2023). This variability highlights the complexity of accurately diagnosing anxiety in CAD patients, necessitating standardized assessment tools and diagnostic criteria to achieve more consistent epidemiological data (Tully et al., 2014). iety is a recognized comorbidity in heart failure patients, with a meta-analysis indicating a 14% prevalence of generalized anxiety disorder, substantially higher than the 3-7% lifetime prevalence observed in the general U.S. population (Celano et al., 2016). This suggests that anxiety is not merely a transient emotional state in cardiac patients but often a diagnosable psychiatric condition requiring dedicated clinical attention (Aquin et al., 2017). While prevalence rates for anxiety disorders in patients with coronary heart disease are comparable to other CHD patient samples, specific subgroups of anxiety disorders, with the exception of specific phobias, exhibit substantially lower prevalence rates (Beer et al., 2020). iety prevalence is reported to be between 10-50% in patients with CAD, though more recent analyses suggest a narrower range of 5-8% (Celano et al., 2016). This discrepancy in reported prevalence rates underscores the need for rigorous, standardized diagnostic approaches in clinical research to accurately characterize the burden of anxiety disorders within this vulnerable population (Tully et al., 2014). Anxiety rates are higher in women across various anxiety disorders and post-traumatic stress disorder, aligning with general population studies and emphasizing the need for sex-specific diagnostic and therapeutic approaches (Beer et al., 2020). The social isolation and fear of illness during the COVID-19 pandemic further exacerbated the incidence of anxiety disorders, particularly among young individuals and women (Moldoveanu et al., 2023). The global burden of anxiety and depression surged significantly in the initial phase of the COVID-19 pandemic, exacerbating pre-existing mental health challenges for many (Amin et al., 2022). This rise further underscores the critical need to address these psychological comorbidities, especially in vulnerable populations such as those with pre-existing conditions like coronary artery disease (Proietti et al., 2011).

Types of Anxiety Disorders

Various anxiety disorders, including generalized anxiety disorder, panic disorder, and specific phobias, manifest distinct clinical presentations and have varying degrees of impact on cardiovascular health. Anxiety can manifest as a trait, reflecting a stable predisposition to experience anxiety, or as a state, representing a transient emotional response to a stressful situation. The clinical presentation of cardiovascular diseases and anxiety frequently overlap, particularly in acute settings, manifesting as atypical chest pain, dyspnea, palpitations, and arrhythmias (Tully et al., 2016). General anxiety disorder is often characterized by excessive worry about various daily life events, whereas panic disorder involves recurrent, unexpected panic attacks accompanied by physical symptoms such as palpitations and shortness of breath. Panic disorder is definded asa discrete period of intense fear or discomfort in which four or more of 13 defined symptoms develop abruptly and reach a peak within 10 minutes (Tully et al., 2014). While the prevalence of any anxiety disorder in patients with coronary heart disease is estimated to be around 15.52%, specific phobias and social phobias often present with markedly lower prevalence rates than other anxiety subtypes (Tully et al., 2014). Specific phobias, though less prevalent, can still significantly impair daily functioning and contribute to poorer quality of life in CAD patients. Cardiophobia, a distinct anxiety subtype, is characterized by a persistent and phobic focus on cardiac function, leading to significant distress and healthcare utilization despite negative medical findings (Eifert, 1992).

Impact on Cardiovascular Outcomes

Anxiety can affect an individual's mood, thinking, and behaviors, and severe anxiety disorders can profoundly affect the quality of life (He et al., 2024). This burden extends to the cardiovascular system, with elevated anxiety levels correlating with an increased risk of incident coronary heart disease and adverse cardiac events (Cohen et al., 2015). While the prevalence of any anxiety disorder in patients with coronary heart disease is estimated to be around 15.52%, specific phobias and social phobias often present with markedly lower prevalence rates than other anxiety subtypes (Tully et al., 2014). Cardiophobia, a distinct anxiety subtype, is characterized by a persistent and phobic focus on cardiac function, leading to significant distress and healthcare utilization despite negative medical findings (Eifert, 1992). This condition, characterized by a persistent and excessive concern with cardiac symptoms and potential heart disease, often leads to avoidance behaviors and repeated medical consultations despite a lack of organic pathology (Zvolensky et al., 2008). Research indicates that while anxiety may serve as a marker for adverse outcomes in patients with cardiac disease, its direct association with mortality often becomes non-significant after controlling for relevant covariates (Celano et al., 2016). anxiety can be viewed as an independent risk factor for the development of coronary heart disease in healthy individuals and a prognostic risk factor in patients already diagnosed with CHD (Roest et al., 2010). This suggests a complex interplay where anxiety might exacerbate existing cardiac conditions or contribute to their progression through various psychophysiological pathways (Roest 2012.Pdf, n.d.). Recent evidence, however, presents conflicting findings regarding anxiety as a prognostic risk factor, with some studies even suggesting significant protective effects of anxiety on coronary heart disease outcomes (Deter et al., 2023). While some unadjusted analyses reveal a link between anxiety and poor cardiac outcomes, including recurrent cardiac events and mortality, these associations frequently diminish or become nonsignificant after controlling for medical and psychological covariates (Celano et al., 2016). This divergence highlights the need for more nuanced research to clarify the precise mechanisms and contexts in which anxiety influences cardiovascular prognosis (Deter et al., 2023). Additionally, heart-focused anxiety, a specific pattern of anxiety symptoms, significantly impacts behavioral cardiac risk factors and quality of life, distinguishing itself from generalized anxiety by its focus on heart-related sensations, avoidance of triggers, and hyper-vigilance to cardiac symptoms (Schmitz et al., 2022). While the mechanisms linking anxiety to cardiopathogenesis are less understood than those for depression, panic disorder and generalized anxiety disorder have consistently demonstrated associations with adverse cardiovascular outcomes (Tully et al., 2016). Anxious physiological responses, including sympathetic overactivity and autonomic dysfunction, which can directly impact cardiovascular health and increase the risk of cardiac events (Janszky et al., 2010). Anxiety can serve as an independent risk factor for the incidence of coronary heart disease and cardiac mortality in initially healthy individuals (Roest et al., 2010).

Clinical Implications

Anxiety, marked by increased physiological arousal and apprehension, is associated with a heightened risk of incident cardiovascular disease and cardiac mortality, even at younger ages (Tully et al., 2016). Anxiety can contribute to the exacerbation of cardiovascular conditions through direct physiological pathways, such as altered heart rate variability and increased systemic inflammation, or indirectly through behavioral factors, including poor medication adherence and unhealthy lifestyle choices (Cohen et al., 2015). Increased anxiety is also associated with a greater risk of myocardial infarction, with some studies indicating a 1.6 times greater risk within a two-hour hazard window prior to an MI (Cohen et al., 2015). Anxiety, in particular, has been linked to the progression of atherosclerosis, reduced heart rate variability, and an elevated risk of ventricular arrhythmias, especially in cases of phobic anxiety (Roest et al., 2010). Elevated anxiety has been associated with impaired flow-mediated dilation of the vasculature, indicating greater endothelial dysfunction (Celano et al., 2016). Anxiety is also linked with an elevated inflammatory response, further contributing to the pathophysiology of cardiovascular diseases (Celano et al., 2016) (Henein et al., 2022). The cumulative effect of anxiety on autonomic nervous system activity and hemodynamics, mirroring the effects of chronic stress, is posited as a primary biological model for its influence on cardiovascular health (Cohen et al., 2015). Anxiety disorders, as well as general distress, are independently associated with an increased risk of incident coronary heart disease (Cohen et al., 2015). Anxious persons having a 48% increased risk of cardiac death (Roest et al., 2010).

Pathophysiology

This dysregulation enhances the inflammatory response of the innate and adaptive immune systems, leading to the initiation or acceleration of pathological processes and worsening of cardiovascular risks (Abboud et al., 2012). Anxiety has been linked to increased levels of inflammatory markers such as C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 (Celano et al., 2016). Chronic anxiety can thus perpetuate a cycle of systemic inflammation, contributing to endothelial dysfunction and the progression of atherosclerosis by altering vascular tone and promoting leukocyte adhesion (Riccioni & Valeriana, 2012). This heightened inflammatory state promotes endothelial damage and plaque instability, thereby increasing the susceptibility to thrombotic events and acute coronary syndromes. Anxiety can also influence the risk of acute coronary events by triggering mechanisms that elevate inflammatory activity, which also accompanies asymptomatic atherosclerosis (Janszky et al., 2010). These inflammatory mediators can also induce a pro-coagulant state, further elevating the risk of thrombotic events and myocardial infarction (Seldenrijk et al., 2011). Anxiety, alongside other psychological stressors, has been shown to contribute to diverse pathophysiological changes, including myocardial infarction, ischemia, and sudden death (Dimsdale, 2008).

Treatment Approaches

First-line pharmacological treatments typically include selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (Bandelow et al., 2017). While some cardiovascular medications, such as beta-blockers and ACE inhibitors, may exert an anxiolytic effect, their primary indication is not anxiety treatment and their psychotropic impact can be equivocal (Repova et al., 2022). Anxiety disorders often necessitate a multifaceted treatment approach that extends beyond pharmacological interventions to include psychotherapy (Tully et al., 2016). Non-pharmacological strategies, such as cognitive-behavioral therapy, relaxation techniques, and mindfulness-based interventions, have shown considerable promise in alleviating anxiety symptoms and improving cardiovascular outcomes in this vulnerable population (Magnon et al., 2021). While cognitive behavioral therapy is an excellent option for addressing both depression and anxiety, its availability can be limited, and patients with significant physical impairments might find regular attendance challenging (Celano et al., 2016) (Celano et al., 2016). Therapeutic interventions like cognitive behavioral therapy for anxiety in patients with cardiovascular disease have shown promise, even in small-scale studies despite limitations such as sample size and randomization issues (Celano et al., 2016). Furthermore, psychotherapy, particularly cognitive behavioral therapy, presents a viable and often preferable alternative to pharmacotherapy for cardiac patients due to its lack of systemic side effects and drug interactions (Celano et al., 2016). While psychological therapy, pharmacotherapy, or a combination of both can be utilized to treat anxiety disorders, cognitive behavioral therapy is considered to have the highest level of evidence among psychotherapies (Bandelow et al., 2017).

Future Directions

Anxiety sensitivity, an independent construct related to anxiety and depression, has emerged as a significant factor adversely associated with exercise participation and may therefore impact cardiac rehabilitation outcomes (Osuji et al., 2022). Monitoring studies also suggest panic is associated with myocardial ischemia, changes in the QT interval, coronary slow-flow, microvascular angina, and arterial stiffness, highlighting several poorly understood mechanisms of cardiopathogenesis that warrant further examination (Tully et al., 2016). Indeed, additional research is warranted to clarify the extent to which depression and anxiety disorders jointly and independently contribute to coronary heart disease prognosis and major adverse cardiovascular events (Tully et al., 2014).

Discussion

Clinical Significance and Prognostic Impact

The findings from this narrative review underscore the substantial clinical significance of anxiety disorders in patients with coronary artery disease. The bidirectional relationship between anxiety and cardiovascular health represents a complex interplay of psychological, physiological, and behavioral factors that significantly impact patient outcomes. The 26% increased risk of cardiac death among anxious individuals, highlights the urgent need for healthcare providers to recognize anxiety as more than a secondary concern in cardiac care. The prevalence of anxiety disorders among cardiovascular patients necessitates a re-evaluation of current diagnostic and treatment paradigms to better integrate mental health considerations into cardiac care (Celano et al., 2016).

The chronic nature of anxiety following acute coronary events, with approximately half of patients experiencing persistent symptoms for up to one year post-event, indicates that anxiety is not merely a transient response to cardiac illness but rather a persistent condition requiring ongoing attention. This chronicity has important implications for long-term cardiovascular prognosis and patient quality of life, necessitating sustained therapeutic intervention rather than brief, episodic treatment approaches.(Parker et al., 2011)

Pathophysiological Mechanisms and Clinical Implications

The pathophysiological pathways linking anxiety to adverse cardiovascular outcomes involve multiple interconnected systems. Autonomic nervous system dysregulation, characterized by altered heart rate variability and increased sympathetic activity, creates a proarrhythmic substrate that may predispose patients to sudden cardiac events. The inflammatory hypothesis is supported by evidence demonstrating elevated levels of systemic inflammatory markers in anxious CAD patients, potentially accelerating atherosclerotic progression and plaque instability.(Celano et al., 2016)

Endothelial dysfunction, as evidenced by impaired flow-mediated dilation, represents another critical mechanism through which anxiety may exacerbate cardiovascular risk. This vascular impairment, combined with increased platelet aggregation and altered coagulation parameters, creates a prothrombotic state that increases the likelihood of acute coronary events.(Frasure-Smith & Lespérance, 2008)

The behavioral pathway, though indirect, may be equally important. Anxiety-related poor medication adherence, reduced engagement in cardiac rehabilitation, and adoption of unhealthy coping mechanisms (such as smoking or sedentary behavior) can significantly undermine optimal cardiovascular management.(Foldes-Busque et al., 2021) Moreover, anxiety can disrupt the delicate balance of the immune system, alter lipid profiles, and negatively influence the coagulation cascade, collectively contributing to adverse cardiovascular outcomes (Abed et al., 2013). This intricate network of physiological and behavioral derangements collectively amplifies the risk of adverse cardiac events, underscoring the critical need for integrated psychosocial interventions in this patient population (Celano et al., 2016). Some scholars propose that anxiety disorders might influence the development of cardiovascular diseases through various pathways, with the most accepted mechanism involving hyperactivation of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system, leading to increased release of plasma catecholamines and endothelial damage, ultimately causing arteriosclerosis, coronary artery disease, and acute coronary events (Zhang et al., 2023). While the precise mechanisms are still being fully elucidated, research suggests a robust association between anxiety disorders and unfavorable cardiovascular outcomes (Silva et al., 2014).

Diagnostic Challenges and Proper Assessment

One of the most significant challenges in managing anxiety in CAD patients is accurate diagnosis. The substantial overlap between somatic symptoms of anxiety (chest pain, palpitations, dyspnea, fatigue) and cardiac symptoms creates diagnostic complexity that frequently leads to misattribution of symptoms and subsequent underdiagnosis of anxiety disorders.(Tully et al., 2016)

Proper Diagnosis Process: The diagnostic process should begin with **systematic screening** using validated instruments, though clinicians must recognize the limitations of self-report questionnaires. The Generalized Anxiety Disorder-7 (GAD-7) questionnaire, while useful for initial screening, should not be considered definitive for diagnosis. The gold standard for diagnosis remains **structured clinical interviews** conducted by trained mental health professionals using DSM-5 or ICD-11 criteria.(Tully et al., 2016)

Differential Diagnosis is crucial and should distinguish between:

- Adaptive anxiety (normal response to cardiac illness)
- Adjustment disorders with anxious features
- Specific anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder)
- Cardiophobia (specific phobia related to cardiac symptoms)
- Anxiety secondary to medical conditions or medications

Clinical Assessment Protocol should include:

1. **Comprehensive psychiatric history** including family history of anxiety disorders
2. **Detailed symptom assessment** focusing on temporal relationships between anxiety symptoms and cardiac events
3. **Medical review** to exclude anxiety secondary to cardiac medications (such as certain inotropes or bronchodilators used in heart failure)

4. **Functional impairment assessment** to determine the impact on daily activities and cardiac rehabilitation participation

5. **Suicide risk assessment**, as anxiety disorders can increase suicide risk, particularly when comorbid with depression(Tully et al., 2016)

Evidence-Based Treatment Approaches

Pharmacological Treatment: First-line pharmacological interventions should focus on **selective serotonin reuptake inhibitors (SSRIs)** and **serotonin-norepinephrine reuptake inhibitors (SNRIs)**, which have demonstrated efficacy in treating anxiety disorders with relatively favorable cardiovascular safety profiles. SSRIs such as sertraline and citalopram have been specifically studied in cardiac populations and show minimal adverse cardiac effects.(Celano et al., 2016)

Important pharmacological considerations for CAD patients include:

- **Drug interactions**: Careful attention to interactions with cardiac medications, particularly warfarin, clopidogrel, and other anticoagulants
- **QT interval monitoring**: Some antidepressants may affect cardiac conduction
- **Starting doses**: Lower initial doses may be appropriate in elderly or frail cardiac patients
- **Monitoring**: Regular assessment of blood pressure, heart rate, and cardiac rhythm during initiation and titration(Celano et al., 2016)

Beta-blockers and ACE inhibitors, while potentially having mild anxiolytic effects, should not be considered primary treatments for anxiety disorders, though they may provide some symptom relief as part of optimal cardiac management.(Parker et al., 2011) Benzodiazepines are generally discouraged as first-line monotherapy due to their addictive potential and central nervous system depressant effects, but they may be considered for short-term use in acute anxiety exacerbations or as adjuncts to SSRIs. Despite these pharmacological strategies, a significant proportion of patients with severe anxiety remain undiagnosed and undertreated, highlighting a critical gap in current clinical practice (Schwarz et al., 2015). This undertreatment is particularly concerning given that cardiac risk factors and symptoms are not notably different in patients with severe anxiety compared to those without, necessitating a similar rigorous evaluation for heart disease (Schwarz et al., 2015).

Non-Pharmacological Interventions: **Cognitive-behavioral therapy (CBT)**

A significant advancement in non-pharmacological treatment for anxiety in cardiac patients is the development of the PATCHD (Panic Attack Treatment in Comorbid Heart Diseases) model(Tully et al., 2016). This specialized cognitive-behavioral therapy approach addresses the unique challenges of treating panic attacks and anxiety in patients with established heart disease, where traditional CBT models may be inadequate or potentially unsafe. The PATCHD intervention consists of six key components delivered over 8 sessions: (1) comprehensive case formulation integrating medical and psychological factors, (2) cardiac-specific psychoeducation about heart disease and anxiety, (3) mindfulness-based stress reduction for physiological awareness and self-regulation, (4) development of individualized chest pain action plans, (5) graded exposures targeting both situational and interoceptive avoidance (including supervised exercise programs), and (6) cognitive restructuring focused on maladaptive illness beliefs and hypervigilant thinking patterns.(Tully et al., 2016)

Additional evidence-based interventions include: (1) Mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy; (2) Relaxation techniques including progressive muscle relaxation and diaphragmatic breathing; (3) Exercise therapy as part of comprehensive cardiac rehabilitation programs; (4) Acceptance and commitment therapy (ACT) showing emerging promise in cardiac populations(Celano et al., 2016)

Integrated Care Models: The implementation of **collaborative care models** that integrate mental health services into cardiac care settings represents an optimal approach to addressing anxiety in CAD patients(Huffman et al., 2014). As (MOSAIC) Randomized Clinical Trial have shown, high-risk cardiac inpatients with mental health disorders benefit significantly from collaborative care management models.(Huffman et al., 2014)

The current study establishes that targeted mental health treatment addressing anxiety and depressive symptomatology, delivered via pharmacological and/or psychotherapeutic interventions, was significantly associated with decreased hazard ratios for hospital readmission (0.25-0.51 depending on treatment modality) and emergency department visits (0.26-0.51 across intervention types). These findings underscore the clinical imperative for integrated mental health services as a core component of comprehensive cardiovascular care to optimize patient outcomes and reduce healthcare resource utilization.(Carmin et al., 2024)

Implementation Challenges and Solutions

Despite the clear evidence supporting the importance of anxiety management in cardiac care, implementation remains suboptimal(Huffman et al., 2014). Limited training of cardiology staff in mental health assessment and intervention, and a pervasive stigma associated with mental health conditions among both patients and healthcare providers (Carmin et al., 2024) (Borkowski & Borkowska, 2024). **Barriers to implementation** include:

- **Knowledge gaps** among healthcare providers regarding anxiety recognition and treatment
- **Resource limitations** including inadequate mental health staffing in cardiac settings
- **Reimbursement challenges** for integrated mental health services
- **Patient factors** including stigma associated with mental health treatment

Proposed solutions include:

- **Educational initiatives** for cardiac care providers on anxiety recognition and basic management
- **Development of clinical pathways** that standardize anxiety screening and referral processes
- **Quality improvement initiatives** that incorporate anxiety outcomes into cardiac care metrics
- **Advocacy for policy changes** that support integrated mental health care in medical settings (Borkowski & Borkowska, 2024).

Future Directions and Research Needs

The conflicting evidence regarding anxiety as a prognostic factor, with some studies suggesting protective effects, highlights the need for more nuanced research approaches.(Tully et al., 2016) Future investigations should focus on:

- **Anxiety subtype specificity** in relation to cardiovascular outcomes
- **Temporal relationships** between anxiety onset and cardiac events
- **Dose-response relationships** between anxiety severity and cardiovascular risk
- **Mediator and moderator analyses** to identify key pathways and patient characteristics
- **Personalized treatment approaches** based on individual risk profiles and treatment preferences (Borkowski & Borkowska, 2024).

Conclusions

Anxiety disorders represent a significant and underappreciated comorbidity in patients with coronary artery disease, with substantial implications for cardiovascular prognosis, quality of life, and healthcare utilization.(Celano et al., 2016) The evidence demonstrates that anxiety functions as an independent risk factor for adverse cardiac outcomes through multiple pathophysiological pathways including autonomic dysregulation, systemic inflammation, and endothelial dysfunction.(Carmin et al., 2024)

The current state of clinical practice reveals significant gaps in the recognition, diagnosis, and treatment of anxiety disorders in cardiac populations. The reliance on self-report screening tools, while practical, often leads to misdiagnosis or underdiagnosis of clinically significant anxiety disorders. Proper diagnostic assessment requires structured clinical interviews conducted by trained mental health professionals, utilizing validated diagnostic criteria.(Borkowski & Borkowska, 2024)

Evidence-based treatment approaches, particularly cognitive-behavioral therapy and selective serotonin reuptake inhibitors, have demonstrated efficacy in reducing anxiety symptoms and potentially improving cardiovascular outcomes. However, the implementation of these interventions remains suboptimal due to systemic barriers including limited resources, inadequate provider training, and insufficient integration of mental health services into cardiac care settings.(Carmin et al., 2024)

Funding Statement: The article did not receive any funding.
Institutional Review and Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflict of Interest Statement: No conflicts of interest to declare.
Acknowledgements: None.

REFERENCES

1. Abboud, F. M., Harwani, S., & Chapleau, M. W. (2012). Autonomic Neural Regulation of the Immune System [Review of Autonomic Neural Regulation of the Immune System]. Hypertension, 59(4), 755. Lippincott Williams & Wilkins. https://doi.org/10.1161/hypertensionaha.111.186833
2. Abed, M. A., Kloub, M. I., & Moser, D. K. (2013). Anxiety and Adverse Health Outcomes Among Cardiac Patients [Review of Anxiety and Adverse Health Outcomes Among Cardiac Patients]. The Journal of Cardiovascular Nursing, 29(4), 354. Lippincott Williams & Wilkins. https://doi.org/10.1097/jcn.0b013e318292b235
3. Amin, M. A., Ahmed, M., Nahin, S., & Kakoly, N. S. (2022). Assessment of Depression and Anxiety Among Admitted People With Heart Disease Conditions: A Cross-Sectional Hospital-Based Study in a Bangladeshi Population During the COVID-19. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.895224
4. Aquin, J. P., El-Gabalawy, R., Sala, T., & Sareen, J. (2017). Anxiety Disorders and General Medical Conditions: Current Research and Future Directions [Review of Anxiety Disorders and General Medical Conditions: Current Research and Future Directions]. FOCUS The Journal of Lifelong Learning in Psychiatry, 15(2), 173. https://doi.org/10.1176/appi.focus.20160044
5. Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience, 17(3), 327. https://doi.org/10.31887/dcns.2015.17.3/bbandelow
6. Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues in Clinical Neuroscience, 19(2), 93. https://doi.org/10.31887/dcns.2017.19.2/bbandelow
7. Batista, L. de C., Salvetti, M. de G., & Butcher, R. de C. G. e S. (2024). Education and Music Intervention to Reduce Anxiety (EMIRA) in Cardiac Catheterization: Intervention Development. Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-4670205/v1
8. Beer, K., Kuhlmann, S. L., Tschorn, M., Arolt, V., Grosse, L., Haverkamp, W., Waltenberger, J., Strehle, J., Martus, P., Müller-Nordhorn, J., Rieckmann, N., & Ströhle, A. (2020). Anxiety disorders and post-traumatic stress disorder in patients with coronary heart disease. Journal of Affective Disorders Reports, 1, 100009. https://doi.org/10.1016/j.jadr.2020.100009
9. Borkowski, P., & Borkowska, N. (2024). Understanding Mental Health Challenges in Cardiovascular Care. Cureus. https://doi.org/10.7759/cureus.54402
10. Carmin, C. N., Ownby, R. L., Fontanella, C. A., Steelesmith, D. L., & Binkley, P. F. (2024). Impact of Mental Health Treatment on Outcomes in Patients With Heart Failure and Ischemic Heart Disease. Journal of the American Heart Association, 13(7). https://doi.org/10.1161/jaha.123.031117
11. Celano, C. M., Daunis, D., Lokko, H. N., Campbell, K. A., & Huffman, J. C. (2016). Anxiety Disorders and Cardiovascular Disease [Review of Anxiety Disorders and Cardiovascular Disease]. Current Psychiatry Reports, 18(11). Springer Science+Business Media. https://doi.org/10.1007/s11920-016-0739-5
12. Celano, C. M., Millstein, R., Bedoya, C. A., Healy, B. C., Roest, A. M., & Huffman, J. C. (2015). Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis [Review of Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis]. American Heart Journal, 170(6), 1105. Elsevier BV. https://doi.org/10.1016/j.ahj.2015.09.013
13. Celano, C. M., Shapter, C., Styra, R., MEd, & Czick, M. E. (2016). Depression and Anxiety in Cardiac Disease. https://www.psychiatrictimes.com/depression/depression-and-anxiety-cardiac-disease
14. Christoph, M., Christoph, A., Dannemann, S., Poitz, D. M., Pfluecke, C., Strasser, R. H., Wunderlich, C., Koellner, V., & Ibrahim, K. (2014). Mental symptoms in patients with cardiac symptoms and normal coronary arteries. Open Heart, 1(1). https://doi.org/10.1136/openhrt-2014-000093
15. Cohen, B. E., Edmondson, D., & Kronish, I. M. (2015). Depression and CVD.
16. Deter, H., Albert, W., Weber, C., Merswolken, M., Orth-Gomér, K., Herrmann-Lingen, C., & Grün, A.-S. (2023). Does Anxiety Affect Survival in Patients with Coronary Heart Disease? Journal of Clinical Medicine, 12(6), 2098. https://doi.org/10.3390/jcm12062098
17. Dimsdale, J. E. (2008). Psychological Stress and Cardiovascular Disease [Review of Psychological Stress and Cardiovascular Disease]. Journal of the American College of Cardiology, 51(13), 1237. Elsevier BV. https://doi.org/10.1016/j.jacc.2007.12.024
18. Eifert, G. H. (1992). Cardiophobia: A paradigmatic behavioural model of heart-focused anxiety and non-anginal chest pain [Review of Cardiophobia: A paradigmatic behavioural model of heart-focused anxiety and non-anginal chest pain]. Behaviour Research and Therapy, 30(4), 329. Elsevier BV. https://doi.org/10.1016/0005-7967(92)90045-i
19. Fernández-Castro, M., Jiménez, J. M., Martín-Gil, B., Muñoz-Moreno, M. F., Martín-Santos, A.-B., Río-García, I. del, Redondo-Pérez, N., & López, M. (2022). The influence of preoperative anxiety on postoperative pain in patients undergoing cardiac surgery. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-20870-9

20. Foldes-Busque, G., Dionne, C. E., Turcotte, S., Tully, P. J., Tremblay, M.-A., Poirier, P., & Denis, I. (2021). Epidemiology and prognostic implications of panic disorder and generalized anxiety disorder in patients with coronary artery disease: rationale and design for a longitudinal cohort study. BMC Cardiovascular Disorders, 21(1). https://doi.org/10.1186/s12872-021-01848-3
21. Frasure-Smith, N., & Lespérance, F. (2008). Depression and Anxiety as Predictors of 2-Year Cardiac Events in Patients With Stable Coronary Artery Disease. Archives of General Psychiatry, 65(1), 62. https://doi.org/10.1001/archgenpsychiatry.2007.4
22. Gorman, J. M. (1996). Comorbid depression and anxiety spectrum disorders [Review of Comorbid depression and anxiety spectrum disorders]. Depression and Anxiety, 4(4), 160. Wiley. https://doi.org/10.1002/(sici)1520-6394(1996)4:4<160::aid-da2>3.0.co;2-j
23. Gutlapalli, S. D., Lavu, V. K., Mohamed, R. A., Huang, R., Potla, S., Bhalla, S., Qabandi, Y. A., Nandula, S. A., Boddepalli, C. S., & Hamid, P. (2022). The Risk of Fatal Arrhythmias in Post-Myocardial Infarction Depression in Association With Venlafaxine [Review of The Risk of Fatal Arrhythmias in Post-Myocardial Infarction Depression in Association With Venlafaxine]. Cureus. Cureus, Inc. https://doi.org/10.7759/cureus.29107
24. He, B., Tan, Z., Lai, K., Qiu, B., & Wang, S. (2024). The effect of event impact on fear of missing out: the chain mediation effect of coping styles and anxiety. Frontiers in Psychology, 15. https://doi.org/10.3389/fpsyg.2024.1382440
25. Henein, M. Y., Vancheri, S., Longo, G., & Vancheri, F. (2022). The Role of Inflammation in Cardiovascular Disease [Review of The Role of Inflammation in Cardiovascular Disease]. International Journal of Molecular Sciences, 23(21), 12906. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ijms232112906
26. Hirschfeld, R. M. A. (2001). The Comorbidity of Major Depression and Anxiety Disorders. The Primary Care Companion For CNS Disorders, 3(6). https://doi.org/10.4088/pcc.v03n0609
27. Huffman, J. C., Celano, C. M., Beach, S. R., Motiwala, S. R., & Januzzi, J. L. (2013). Depression and Cardiac Disease: Epidemiology, Mechanisms, and Diagnosis. Cardiovascular Psychiatry and Neurology, 2013, 1. https://doi.org/10.1155/2013/695925
28. Huffman, J. C., Mastromauro, C. A., Beach, S. R., Celano, C. M., DuBois, C. M., Healy, B. C., Suarez, L., Rollman, B. L., & Januzzi, J. L. (2014). Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac Events The Management of Sadness and Anxiety in Cardiology (MOSAIC) Randomized Clinical Trial.
29. Janszky, I., Ahnve, S., Lundberg, I. E., & Hemmingsson, T. (2010). Early-Onset Depression, Anxiety, and Risk of Subsequent Coronary Heart Disease. Journal of the American College of Cardiology, 56(1), 31. https://doi.org/10.1016/j.jacc.2010.03.033
30. Jha, M. K., Qamar, A., Vaduganathan, M., Charney, D. S., & Murrough, J. W. (2019). Screening and Management of Depression in Patients With Cardiovascular Disease [Review of Screening and Management of Depression in Patients With Cardiovascular Disease]. Journal of the American College of Cardiology, 73(14), 1827. Elsevier BV. https://doi.org/10.1016/j.jacc.2019.01.041
31. Kariuki-Nyuthe, C., & Stein, D. J. (2014). Anxiety and Related Disorders and Physical Illness. In Key issues in mental health (Online)/Key issues in mental health (Print) (p. 81). Karger Publishers. https://doi.org/10.1159/000365538
32. Kustrzycki, W., Rymaszewska, J., Malcher, K., Szczepańska-Gieracha, J., & Biecek, P. (2011). Risk factors of depressive and anxiety symptoms 8 years after coronary artery bypass grafting. European Journal of Cardio-Thoracic Surgery, 41(2), 302. https://doi.org/10.1016/j.ejcts.2011.06.028
33. Li, J., Ji, F., Song, J., Gao, X., Jiang, D., Chen, G., Chen, S., Lin, X., & Zhuo, C. (2020). Anxiety and clinical outcomes of patients with acute coronary syndrome: a meta- analysis.
34. Magnon, V., Dutheil, F., & Vallet, G. T. (2021). Benefits from one session of deep and slow breathing on vagal tone and anxiety in young and older adults. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-98736-9
35. Moldoveanu, A., Mitruț, O., Jinga, N., Petrescu, C., Moldoveanu, F., Asavei, V., Anghel, A. M., & Petrescu, L. (2023). Immersive Phobia Therapy through Adaptive Virtual Reality and Biofeedback. Applied Sciences, 13(18), 10365. https://doi.org/10.3390/app131810365
36. Osuji, E., Prior, P. L., Suskin, N., Frisbee, J. C., & Frisbee, S. J. (2022). The relationship between anxiety sensitivity and clinical outcomes in cardiac rehabilitation: A scoping review [Review of The relationship between anxiety sensitivity and clinical outcomes in cardiac rehabilitation: A scoping review]. American Journal of Preventive Cardiology, 12, 100376. Elsevier BV. https://doi.org/10.1016/j.ajpc.2022.100376
37. Parker, G., Hyett, M. P., Hadži-Pavlović, D., Brotchie, H., & Walsh, W. (2011). GAD is good? Generalized anxiety disorder predicts a superior five-year outcome following an acute coronary syndrome. Psychiatry Research, 188(3), 383. https://doi.org/10.1016/j.psychres.2011.05.018
38. Proietti, R., Mapelli, D., Volpe, B., Bartoletti, S., Sagone, A., Bianco, L. D., & Daliento, L. (2011). Mental Stress and Ischemic Heart Disease: Evolving Awareness of a Complex Association [Review of Mental Stress and Ischemic Heart Disease: Evolving Awareness of a Complex Association]. Future Cardiology, 7(3), 425. Future Medicine. https://doi.org/10.2217/fca.11.13

39. Repova, K., Aziriova, S., Krajcirovicova, K., & Šimko, F. (2022). Cardiovascular therapeutics: A new potential for anxiety treatment? [Review of Cardiovascular therapeutics: A new potential for anxiety treatment?]. Medicinal Research Reviews, 42(3), 1202. Wiley. https://doi.org/10.1002/med.21875
40. Riccioni, G., & Valeriana, S. (2012). Atherosclerosis: from biology to pharmacological treatment. Journal of Geriatric Cardiology, 9(3), 305. https://doi.org/10.3724/sp.j.1263.2012.02132
41. Roest 2012.pdf. (n.d.).
42. Roest, A. M., Martens, E. J., de Jonge, P., & Denollet, J. (2010). Anxiety and Risk of Incident Coronary Heart Disease: A Meta-analysis.
43. Roy-Byrne, P., Davidson, K. W., Kessler, R. C., Asmundson, G. J. G., Goodwin, R. D., Kubzansky, L. D., Lydiard, R. B., Massie, M. J., Katon, W., Laden, S. K., & Stein, M. B. (2008). Anxiety disorders and comorbid medical illness [Review of Anxiety disorders and comorbid medical illness]. General Hospital Psychiatry, 30(3), 208. Elsevier BV. https://doi.org/10.1016/j.genhosppsych.2007.12.006
44. Satyaprakash, S., Behari, M., & Das, S. (2018). Psychiatric Co-Morbidity Among Patients of Chest Pain Posted for Coronary Angiography. International Journal of Contemporary Medical Research [IJCMR], 5(4). https://doi.org/10.21276/ijcmr.2018.5.4.32
45. Schmitz, C., Wedegärtner, S. M., Langheim, E., Kleinschmidt, J., & Köllner, V. (2022). Heart-Focused Anxiety Affects Behavioral Cardiac Risk Factors and Quality of Life: A Follow-Up Study Using a Psycho-Cardiological Rehabilitation Concept. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.836750
46. Schwarz, J., Prashad, A., & Winchester, D. E. (2015). Prevalence and Implications of Severe Anxiety in a Prospective Cohort of Acute Chest Pain Patients. Critical Pathways in Cardiology A Journal of Evidence-Based Medicine, 14(1), 44. https://doi.org/10.1097/hpc.0000000000000038
47. Seldenrijk, A., Hout, H. van, Marwijk, H. van, Groot, E. de, Gort, J., Rustemeijer, C., Diamant, M., & Penninx, B. W. J. H. (2011). Depression, Anxiety, and Arterial Stiffness. Biological Psychiatry, 69(8), 795. https://doi.org/10.1016/j.biopsych.2010.12.034
48. Silva, C. T. B. da, Silva, A. M. V. da, Costa, M. de A., Sant'Anna, R. T., Heldt, E., & Manfro, G. G. (2014, October 28). Increased anxiety levels predict a worse endothelial function in patients with lifetime panic disorder: Results from a naturalistic follow-up study. In International Journal of Cardiology (Vol. 179, p. 390). Elsevier BV. https://doi.org/10.1016/j.ijcard.2014.10.170
49. Sullivan, M. D., LaCroix, A. Z., Spertus, J. A., & Hecht, J. (2000). Five-year prospective study of the effects of anxiety and depression in patients with coronary artery disease. The American Journal of Cardiology, 86(10), 1135. https://doi.org/10.1016/s0002-9149(00)01174-7
50. Trotter, R., Gallagher, R., & Donoghue, J. (2010). Anxiety in patients undergoing percutaneous coronary interventions. Heart & Lung, 40(3), 185. https://doi.org/10.1016/j.hrtlng.2010.05.054
51. Tully, P. J., Cosh, S., & Baumeister, H. (2014). The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease [Review of The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease]. Journal of Psychosomatic Research, 77(6), 439. Elsevier BV. https://doi.org/10.1016/j.jpsychores.2014.10.001
52. Tully, P. J., Harrison, N. J., Cheung, P., & Cosh, S. (2016). Anxiety and Cardiovascular Disease Risk: a Review [Review of Anxiety and Cardiovascular Disease Risk: a Review]. Current Cardiology Reports, 18(12). Springer Science+Business Media. https://doi.org/10.1007/s11886-016-0800-3
53. Tully, P. J., Sardinha, A., & Nardi, A. E. (2016). A New CBT Model of Panic Attack Treatment in Comorbid Heart Diseases (PATCHD): How to Calm an Anxious Heart and Mind. Cognitive and Behavioral Practice, 24(3), 329. https://doi.org/10.1016/j.cbpra.2016.05.008
54. Watkins, L. L., Blumenthal, J. A., Babyak, M. A., Davidson, J., McCants, C. B., O'Connor, C., & Sketch, M. H. (2010). Phobic Anxiety and Increased Risk of Mortality in Coronary Heart Disease. Psychosomatic Medicine, 72(7), 664. https://doi.org/10.1097/psy.0b013e3181e9f357
55. Zhang, Z., Xing, W., Wei, J., Yu-hui, W., & Luo, C. (2023). Does anxiety cause angina recurrence after percutaneous coronary intervention in patients with STEMI? Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1283182
56. Zvolensky, M. J., Feldner, M. T., Eifert, G. H., Vujanovic, A. A., & Solomon, S. E. (2008). Cardiophobia: A Critical Analysis. Transcultural Psychiatry, 45(2), 230. https://doi.org/10.1177/1363461508089766